Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

A route to new cancer therapies: the FA pathway is essential in BRCA1- or BRCA2-deficient cells

Nature Structural & Molecular Biology volume 23, pages 701–703 (2016)Cite this article

Subjects

Mutations in the BRCA1 and BRCA2 genes strongly predispose carriers to breast and ovarian cancers. Two new studies reveal that FANCD2, a key component of the Fanconi anemia pathway, is essential for the survival of cells with BRCA1 or BRCA2 mutations. These findings pave the way for new 'synthetic lethal' strategies to kill BRCA-mutated cancers.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: FANCD2 protects replication forks and prevents cell death in cancers deficient in BRCA1 or BRCA2 (BRCA1/2).
Figure 2: Strategy to selectively target BRCA1- or BRCA2-deficient cancers by inhibiting FANCD2 function.

References

  1. Easton, D.F. Breast Cancer Res. 1, 14–17 (1999).

    Article  CAS  Google Scholar 

  2. Michl, J., Zimmer, J., Buffa, F.M., McDermott, U. & Tarsounas, M. Nat. Struct. Mol. Biol. 23, 755–757 (2016).

    Article  CAS  Google Scholar 

  3. Kais, Z. et al. Cell Rep. 15, 2488–2499 (2016).

    Article  CAS  Google Scholar 

  4. Michl, J., Zimmer, J. & Tarsounas, M. EMBO J. 35, 909–923 (2016).

    Article  CAS  Google Scholar 

  5. Kim, H. & D'Andrea, A.D. Genes Dev. 26, 1393–1408 (2012).

    Article  CAS  Google Scholar 

  6. Lossaint, G. et al. Mol. Cell 51, 678–690 (2013).

    Article  CAS  Google Scholar 

  7. Schlacher, K., Wu, H. & Jasin, M. Cancer Cell 22, 106–116 (2012).

    Article  CAS  Google Scholar 

  8. Zhang, J. Cell Biosci. 3, 11 (2013).

    Article  CAS  Google Scholar 

  9. Schlacher, K. et al. Cell 145, 529–542 (2011).

    Article  CAS  Google Scholar 

  10. Howlett, N.G. et al. Science 297, 606–609 (2002).

    Article  CAS  Google Scholar 

  11. Sawyer, S.L. et al. Cancer Discov. 5, 135–142 (2015).

    Article  CAS  Google Scholar 

  12. Zeman, M.K. & Cimprich, K.A. Nat. Cell Biol. 16, 2–9 (2014).

    Article  CAS  Google Scholar 

  13. Mateos-Gomez, P.A. et al. Nature 518, 254–257 (2015).

    Article  CAS  Google Scholar 

  14. Ceccaldi, R. et al. Nature 518, 258–262 (2015).

    Article  CAS  Google Scholar 

  15. Boisvert, R.A. & Howlett, N.G. Cell Cycle 13, 2999–3015 (2014).

    Article  CAS  Google Scholar 

  16. Kee, Y. & D'Andrea, A.D. Genes Dev. 24, 1680–1694 (2010).

    Article  CAS  Google Scholar 

  17. Lachaud, C. et al. Science 351, 846–849 (2016).

    Article  CAS  Google Scholar 

  18. Lord, C.J., Tutt, A.N. & Ashworth, A. Annu. Rev. Med. 66, 455–470 (2015).

    Article  CAS  Google Scholar 

  19. Bouwman, P. & Jonkers, J. Clin. Cancer Res. 20, 540–547 (2014).

    Article  CAS  Google Scholar 

  20. Halazonetis, T.D., Gorgoulis, V.G. & Bartek, J. Science 319, 1352–1355 (2008).

    Article  CAS  Google Scholar 

  21. Di Micco, R., Fumagalli, M. & d'Adda di Fagagna, F. Trends Cell Biol. 17, 529–536 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Christophe Lachaud and John Rouse are at the MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, Sir James Black Centre, University of Dundee, Dundee, Scotland, UK.,

    Christophe Lachaud & John Rouse

Authors
  1. Christophe Lachaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Rouse
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Rouse.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lachaud, C., Rouse, J. A route to new cancer therapies: the FA pathway is essential in BRCA1- or BRCA2-deficient cells. Nat Struct Mol Biol 23, 701–703 (2016). https://doi.org/10.1038/nsmb.3276

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nsmb.3276

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer